|Drug Name||GPCR-targeted Project 002|
Sphingosine 1-phosphate (S1P) is a member of a class of lipids called sphingolipids that are involved in stimulating angiogenesis and mediating fibrosis. A first-in-class monoclonal antibody targeting sphingosine 1-phosphate receptor 1 (S1PR1) is developed for the treatment of autoimmune diseases such as multiple sclerosis and inflammation.
|Target||Sphingosine 1-phosphate receptor 1 (S1PR1)|
|Drug Modality||Monoclonal antibody|
|Indication||Autoimmune diseases; Inflammation|
|Mechanism of Action||S1PR1 agonists|
We look forward to hearing from you.